← Back to Search

Ultrasound Therapy

ExAblate for Essential Tremor (ET004 Trial)

Waitlist Available
Led By Nir Lipsman
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up treatment through 1 month
Awards & highlights


This study is evaluating whether AF echo imaging is safe and feasible for use in the brain.

Eligible Conditions
  • Essential Tremor
  • Tremor
  • Neurologic Symptoms


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~treatment through 1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and treatment through 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Device and Procedure related Adverse Events

Trial Design

1Treatment groups
Experimental Treatment
Group I: ExAblate 4000 SystemExperimental Treatment1 Intervention
ExAblate Neuro system to perform AF echo imaging in treatment of Essential Tremor
First Studied
Drug Approval Stage
How many patients have taken this drug

Find a Location

Who is running the clinical trial?

InSightecLead Sponsor
89 Previous Clinical Trials
3,694 Total Patients Enrolled
12 Trials studying Essential Tremor
1,048 Patients Enrolled for Essential Tremor
Nir LipsmanPrincipal InvestigatorSunnybrook Health Science Centre
~3 spots leftby Jul 2025